Palus, Sandra

[["dc.bibliographiccitation.firstpage","19"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","21"],["dc.bibliographiccitation.volume","238"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Springer, J. I."],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Anker, Markus S."],["dc.contributor.author","Anker, Stefan-D."],["dc.date.accessioned","2018-11-07T10:22:26Z"],["dc.date.available","2018-11-07T10:22:26Z"],["dc.date.issued","2017"],["dc.description.abstract","Approximately 40-50% of the population over 80 years of age suffers from sarcopenia making this condition a major geriatric clinical disorder and a key challenge to healthy aging. The hallmark symptom of sarcopenia is the loss of muscle mass and strength without the loss of overall body weight. Sarcopenic patients are likely to have worse clinical outcomes and higher mortality compared to healthy individuals. This review will focus on animal models designed to study sarcopenia including hind-limb unloading, de-nervation, and immobilization by using casts or wire strategies, as well as using aged rodents. Currently there are no registered treatments for sarcopenia. Most sarcopenic individuals show signs of physical frailty, which leads to increases the prevalence of balance disorders, falls, fractures and pain. Therefore, is it essential to develop and use relevant animal models to further the research on sarcopenia therapy? (C) 2017 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.ijcard.2017.03.152"],["dc.identifier.isi","000402478900004"],["dc.identifier.pmid","28465116"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42272"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","1874-1754"],["dc.relation.issn","0167-5273"],["dc.title","Models of sarcopenia: Short review"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","jcsm.13009"],["dc.bibliographiccitation.journal","Journal of Cachexia, Sarcopenia and Muscle"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Elkina, Yulia"],["dc.contributor.author","Braun, Tanja"],["dc.contributor.author","Haehling, Stephan"],["dc.contributor.author","Döhner, Wolfram"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Cerami, Anthony"],["dc.contributor.author","Brines, Michael"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2022-06-01T09:39:03Z"],["dc.date.available","2022-06-01T09:39:03Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1002/jcsm.13009"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108378"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-572"],["dc.relation.eissn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.title","The erythropoietin‐derived peptide ARA 284 reduces tissue wasting and improves survival in a rat model of cancer cachexia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","89"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.bibliographiccitation.lastpage","97"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Musolino, Vincenzo"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Latouche, Celine"],["dc.contributor.author","Gliozzi, Micaela"],["dc.contributor.author","Bosco, Francesca"],["dc.contributor.author","Scarano, Federica"],["dc.contributor.author","Nucera, Saverio"],["dc.contributor.author","Carresi, Cristina"],["dc.contributor.author","Scicchitano, Miriam"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Jaisser, Frederic"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Mollace, Vincenzo"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2020-12-10T14:06:09Z"],["dc.date.available","2020-12-10T14:06:09Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1002/ehf2.v6.1"],["dc.identifier.issn","2055-5822"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69800"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Cardiac expression of neutrophil gelatinase-associated lipocalin in a model of cancer cachexia-induced cardiomyopathy"],["dc.title.alternative","Cardiac expression of NGAL in cancer cachexia-induced cardiomyopathy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","jcsm.13116"],["dc.bibliographiccitation.journal","Journal of Cachexia, Sarcopenia and Muscle"],["dc.contributor.author","Yuan, Luping"],["dc.contributor.author","Springer, Jochen"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Busquets, Silvia"],["dc.contributor.author","Jové, Queralt"],["dc.contributor.author","Alves de Lima Junior, Edson"],["dc.contributor.author","Anker, Markus S."],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Álvarez Ladrón, Natalia"],["dc.contributor.author","Millman, Oliver"],["dc.contributor.author","Argiles, Josep M."],["dc.date.accessioned","2022-12-01T08:31:17Z"],["dc.date.available","2022-12-01T08:31:17Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1002/jcsm.13116"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118130"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.eissn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.title","The atypical β‐blocker S‐oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","640"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","644"],["dc.bibliographiccitation.volume","176"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2018-11-07T09:33:30Z"],["dc.date.available","2018-11-07T09:33:30Z"],["dc.date.issued","2014"],["dc.description.abstract","The syndrome of cachexia, i.e, involuntary weight loss in patients with underlying diseases, sarcopenia, i.e, loss of muscle mass due to ageing, and general muscle atrophy from disuse and/or prolonged bed rest have received more attention over the last decades. All lead to a higher morbidity and mortality in patients and therefore, they represent a major socio-economic burden for the society today. This mini-review looks at recent developments in basic research that are relevant to the loss of skeletal muscle. It aims to cover the most significant publication of last three years on the causes and effects of muscle wasting, new targets for therapy development and potential biomarkers for assessing skeletal muscle mass. The targets include 1) E-3 ligases: TRIM32, SOCS1 and SOCS3 by involving the elongin BC ubiquitin-ligase, Cbl-b, culling 7, Fbx040, MG53 (TRIM72) and the mitochondrial Mull, 2) the kinase MST1 and 3) the G-protein G alpha i(2) D(3)-creatine has the potential to be used as a novel biomarker that allows to monitor actual change in skeletal muscle mass over time. In conclusion, significant development efforts are being made by academic groups as well as numerous pharmaceutical companies to identify new targets and biomarkers muscle, as muscle wasting represents a great medical need, but no therapies have been approved in the last decades. (C) 2014 Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.ijcard.2014.08.086"],["dc.identifier.isi","000343893300037"],["dc.identifier.pmid","25205489"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31979"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","1874-1754"],["dc.relation.issn","0167-5273"],["dc.title","Muscle wasting: An overview of recent developments in basic research"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","377"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","378"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Konishi, Masaaki"],["dc.contributor.author","Drescher, C."],["dc.contributor.author","Pelgrim, Loes"],["dc.contributor.author","Tschirner, Anika"],["dc.contributor.author","Baumgarten, A."],["dc.contributor.author","von Haehling, S."],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Anker, Stefan-D."],["dc.contributor.author","Springer, J. I."],["dc.date.accessioned","2018-11-07T09:57:28Z"],["dc.date.available","2018-11-07T09:57:28Z"],["dc.date.issued","2015"],["dc.identifier.isi","000366200403455"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37162"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.issn","1879-0844"],["dc.relation.issn","1388-9842"],["dc.title","Febuxostat reduces cancer cachexia-induced cardiomyopathy"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.contributor.author","Suzuki, Tsuyoshi"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2020-12-10T14:06:10Z"],["dc.date.available","2020-12-10T14:06:10Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1002/ehf2.12387"],["dc.identifier.eissn","2055-5822"],["dc.identifier.issn","2055-5822"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69802"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Skeletal muscle wasting in chronic heart failure"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","312"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","317"],["dc.bibliographiccitation.volume","218"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","Hatanaka, Michiyoshi"],["dc.contributor.author","Konishi, Masaaki"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Anker, Stefan-D."],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2018-11-07T10:09:59Z"],["dc.date.available","2018-11-07T10:09:59Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Erythropoietin administration, which is clinically used in cancer patients with cancer-induced anemia, has also potentially beneficial effects on nonhematopoietic organs. We assessed the effects of erythropoietin on cancer cachexia progression and cardiac wasting compared with placebo using the Yoshida hepatoma model. Methods: Wistar rats were divided in a sham group (n = 10) and a tumor-bearing group (n = 60). The tumor-bearing group was further randomized to placebo (n = 28), 500 Unit/kg/day (n = 16) or 5000 Unit/kg/day of erythropoietin (n = 16). Body composition was measured using nuclear magnetic resonance spectroscopy, cardiac function using echocardiography, physical activity using infrared monitoring system. Results: Tumor-bearing rats with high dose erythropoietin led to a significant improvement on survival compared with placebo (hazard ratio: 0.43, 95% CI: 0.20-0.92, p = 0.030), though low dose erythropoietin did not reach significance (hazard ratio: 0.46, 95% CI: 0.22-1.02, p = 0.056). Loss of body weight, wasting of lean mass, fat mass, and reduced physical activity were ameliorated in rats treated with both low and high doses of erythropoietin (p < 0.05, all). Moreover, reduced left ventricularmass and left ventricular systolic function were also ameliorated in rats treated with low and high doses of erythropoietin (p < 0.05, respectively). Conclusions: Overall, the present data support that cardiac wasting induced by cancer cachexia plays an important rolewhich leads to impaired survival, provided that the erythropoietin could be an effective therapeutic approach for cancer cachexia progression and cardiac wasting. (C) 2016 Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.ijcard.2016.05.008"],["dc.identifier.isi","000377856300052"],["dc.identifier.pmid","27240157"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39764"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","1874-1754"],["dc.relation.issn","0167-5273"],["dc.title","Erythropoietin improves cardiac wasting and outcomes in a rat model of liver cancer cachexia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]